http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022098685-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e974c8a148aa6bf505c7e049484889e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae10212794160b34478f0d05b6ab6fd7 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-804 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-4631 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-464417 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2021-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a83afa52e5d25ecb6d5d92fe71815bea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_783880b08fe2409d94be2866a5c13f9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_766a017e3700aa1c526f0a50ec591b98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f8488a498ef53d19b2c585d725f68bb |
publicationDate | 2022-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2022098685-A2 |
titleOfInvention | Car t cell therapy in patients who have had prior anti-cancer alkylator therapy |
abstract | Provided herein are uses of chimeric antigen receptors (CARs) for treating a tumor or a cancer (such as B cell related cancer, e.g., multiple myeloma). In addition, an optimal washout period for commencing a therapy for the treatment of a condition in a subject after a prior exposure can be determined by receiving, for each of a plurality of subjects, prior treatment history data. Left-censored data can then be derived from the prior treatment history data for each of the subjects that includes a washout period and event or censor. A time scale of the left- censored treatment data is then inverted to result in right-censored treatment data. The right- censored treatment data is then applied to a time-to-event (TTE) model that associates one or more variables of interest with a time since exposure to the prior exposure. A maximally selected log-rank statistic across a plurality of cutoffs within a pre-defined percentile range is computed for continuous variables within the one or more variables of interest. One or more variables and associated cutoffs for the continuous variables having a maximally selected log- rank statistic below a first pre-defined threshold are then identified. A test statistic of each (n-1) strata relative to a reference stratum is then computed for ordinal or categorical variables within the one or more variables of interest. One or more ordinary or categorical variables and associated strata having a test statistic below a second pre-defined threshold, relative to the reference stratum are identified. An optimal washout period is then determined for the therapy based on the cutoff having a lowest value below the pre-defined threshold and relative to a median of subject values below the pre-defined threshold and a median of subject values above the pre-defined threshold. |
priorityDate | 2020-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 598.